Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation
This article was originally published in The Tan Sheet
Executive Summary
Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.
You may also be interested in...
Industry Roundup: GMPs, DXM, Pharmascience, Rock Creek
Herbal firm crosses GMP, claims lines; Kentucky makes 8 to age-restrict DXM sales; Pharmascience expands with Quebec support; Rock Creek closes share offerings; and more news in brief.
Industry Roundup: GMPs, DXM, Pharmascience, Rock Creek
Herbal firm crosses GMP, claims lines; Kentucky makes 8 to age-restrict DXM sales; Pharmascience expands with Quebec support; Rock Creek closes share offerings; and more news in brief.
Industry News Roundup
DASCA facilitates DEA’s steroid scheduling; U.K. ad authority sneezes at hay fever claim; Nutroganics acquires Wholesoy; hemp migraine relief distribution lit; Clif’s cashew recipe trips some customers; ONHA sponsors GrassrootsHealth nutrient research; baby wipe recall reaches 4M units; and Nasdaq reprieve for Rock Creek.